Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to determine the safety and efficacy of ONO-5046Na in patients with acute respiratory failure associated with community-acquired pneumonia
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| P | Placebo Comparator |
| |
| E | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| ONO-5046Na | Drug | twenty four hour infusion at 0 mg/kg/hr for 14 days |
| |
| Measure | Description | Time Frame |
|---|---|---|
| pulmonary function | 14 days |
| Measure | Description | Time Frame |
|---|---|---|
| mortality | 28 days | |
| ventilator status | 28 days |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Koji Takehara | Ono Pharmaceutical Co., Ltd. | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Chugoku Region | Chugoku | Japan | ||||
| Chubu Region |
Not provided
Not provided
Not provided
Not provided
Not provided
| ONO-5046Na |
| Drug |
twenty four hour intravenous infusion at 0.2 mg/kg/hr for 14 days |
|
| Chūbu |
| Japan |
| Hokkaido Region | Hokkaido | Japan |
| Hokuriku Region | Hokuriku | Japan |
| Kanto Region | Kanto | Japan |
| Kinki Region | Kinki | Japan |
| Kyushu Region | Kyushu | Japan |
| Shikoku Region | Shikoku | Japan |
| Tohoku Region | Tohuku | Japan |
| ID | Term |
|---|---|
| D000098968 | Community-Acquired Pneumonia |
| ID | Term |
|---|---|
| D017714 | Community-Acquired Infections |
| D007239 | Infections |
| D011014 | Pneumonia |
| D012141 | Respiratory Tract Infections |
| D012140 | Respiratory Tract Diseases |
Not provided
Not provided